Ra Pharma (RARX) PT Lowered to $43 at Raymond James
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
Tweet
Share
E-mailGet Alerts RARX Hot Sheet
Price: $48.00 --0%
Rating Summary:
0 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Rating Summary:
0 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Join SI Premium – FREE
Raymond James analyst Steven Seedhouse lowered the price target on Ra Pharma (NASDAQ: RARX) to $43.00 (from $49.00) while maintaining a Strong Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Datadog (DDOG) PT Lowered to $275 at TD Cowen
- CAVA Group Inc (CAVA) PT Lowered to $60 at DA Davidson
- Expedia (EXPE) PT Raised to $320 at Cantor Fitzgerald
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Raymond JamesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
